Law360, New York (December 07, 2006) -- After a seven-day bench trial, attorneys for Pfizer Inc. and generic drug maker Mylan Pharmaceuticals Inc. made closing arguments Wednesday, putting the final touch on a longstanding patent infringement suit over Pfizer’s blockbuster drug Norvasc.
Now that the trial before Judge Terrence F. McVerry of the U.S. District Court Western District of Pennsylvania has wrapped up, both parties await a decision as to whether or...
